NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

–Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA^®—

–All three of NGM Bio’s wholly-owned myeloid reprogramming product candidates –NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 – are now in the clinic–

–NGM Bio is implementing a biomarker strategy across NGM707, NGM831 and NGM438 designed to assess target engagement and guide dose selection, to demonstrate proof-of-mechanism and to potentially enable patient selection strategies–

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors. With the initiation of this trial, all three of NGM Bio’s wholly-owned myeloid checkpoint inhibition and reprogramming product candidates – NGM438, a LAIR1 antagonist antibody; NGM707, a dual ILT2/ILT4 antagonist antibody; and NGM831, an ILT3 antagonist antibody – are now in the clinic. ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironment. NGM707, NGM831 and NGM438 are engineered to release distinct myeloid checkpoints and reprogram myeloid cells to reverse immune suppression and enhance immune response in tumors.

Click the button below to read the entire Press Release:

Continue Reading The Press Release